Physician profile
Anna Lines
NPI 1114433828
$7,177.72
in general payments reported to CMS, 2019-2025
41 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $704 · 2022: $2,158 · 2023: $1,621 · 2024: $1,432 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,315.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $956.88 | 2021-2025 | |
| Novo Nordisk INC | $812.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $699.15 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $528.04 | 2021-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $353.09 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $304.95 | 2022-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.71 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $258.86 | 2021-2025 | Repatha, Otezla, Prolia |
| Radius Health, INC. | $256.43 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $249.37 | 2022-2023 | |
| Pfizer INC. | $236.60 | 2022-2025 | |
| Axsome Therapeutics, INC. | $183.07 | 2023-2025 | Auvelity, Sunosi |
| Abbott Laboratories | $175.87 | 2021-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $175.52 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $158.50 | 2021-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Lines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.